Notably, MPI has been shown to potentiate therapeutic responses in acute myeloid leukemia, enhancing cellular sensitivity to both conventional cytarabine chemotherapy and targeted FLT3 inhibitors [71]. Here, FLT3 is linked to acute myeloid leukemia.